Projects
Search from 1147 projects:
1147 Project(s)
GA29144/Bergamot
Aug 1, 2017A PHASE III, RANDOMIZED, DOUBLEBLIND, PLACEBOCONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ETROLIZUMAB AS AN INDUCTION AND MAINTENANCE TREATMENT FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE
Clinical Studies - Aug 1, 2017 - Aug 1, 2021
Automatically Closed
Project leader: Borovicka Jan, Brand Stephan
Members: Dora Barbara, Frei Remus, Knellwolf Christina, Semadeni Gian-Marco, Sulz Michael
ICL670, Deferasirox
Aug 1, 2017A phase II, multicenter, open-label, randomized two-year study to evaluate the efficacy and safety of deferasirox film-coated tablet versus phlebotomy in patients with Hereditary Hemochromatosis
Clinical Studies - Aug 1, 2017 - Jan 1, 2020
Completed
Project leader: Semela David
Members: Stillhard Roman
LEADERS FREE III
Aug 1, 2017A study evaluating the safety and efficacy of the BioFreedomTM Biolimus A9TM coated Cobalt Chromium coronary stent system in patients at high risk of bleeding. The objective of this study is to evaluate if the BioFreedomTM CoCr Drug Coated stent has...
Clinical Studies - Aug 1, 2017 - Dec 31, 2021
Completed
Project leader: Weilenmann Daniel
Members: Vetsch Susanne
CLL13-TRIAL OF THE GCLLSG IN COOPERATION WITH HOVON, NORDIC CLL STUDY GROUP AND SAKK (THE GA101 IBRUTINIB ABT101 (GAIA) TRIAL): A PHASE 3 MULTICENTER, RANDOMIZED, PROSPECTIVE, OPEN-LABEL TRIAL OF STANDARD CHEMOIMMUNOTHERAPY (FCR/BR) VERSUS RITUXIMAB PLUS VENETOCLAX (RVE) VERSUS OBINUTUZUMAB (GA101) PLUS VENETOCLAX (GVE) VERSUS OBINUTUZUMAB PLUS IBRUTINIB PLUS VENETOCLAX (GIVE) IN FIT PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITHOUT DEL(17P) OR TP53 MUTATION
Jul 17, 2017Chemoimmunotherapy is the standard of care in first-line treatment of CLL patients without del17p or TP 53 mutation; physically fit patients are treated with fludarabine, cyclophosphamide and rituximab (FCR)1. Due to the high risk of severe neutropen...
Clinical Studies - Jul 17, 2017 - Feb 29, 2024
Automatically Closed
Project leader: Baumann Michael
QLQ-CAX24 Phase4
Jul 17, 2017The aim of the present study is to test the scale structure, reliability, responsiveness to change and validity of the EORTC QLQ-CAX24 in conjunction with the EORTC QLQ-C30 in people diagnosed with cancer cachexia with different primary cancer diagno...
Clinical Studies - Jul 17, 2017 - Oct 1, 2017
Automatically Closed
Project leader: Strasser Florian
Members: Domeisen Benedetti Franzisca, Attoun-Knobel Suzanne
TOASST
Jul 8, 2017Die Studie soll die Hypothese prüfen, dass auch nach längerer Behandlungsdauer mit Prednison®, Spiricort® oder einem verwandten Produkt auf ein langsames Ausschleichen der Dosis verzichtet werden darf, ohne dass dadurch ein schlechterer Verlauf resul...
Clinical Studies - Jul 8, 2017 - Jun 8, 2020
Automatically Closed
Project leader: Brändle Michael
Members: Hörburger David, Baerlocher Lorenz
ENTRUST DSE-EDO-01-15-EU
Jul 7, 2017Beurteilung der Sicherheit und Wirksamkeit eines Edoxabanbasierten , verglichen mit einem Vitamin-K-Antagonist-basierten, antithrombotischen Therapieregimes nach einer erfolgreichen perkutanen Koronarintervention (PCI) mit Stent-Implantation, bei Pat...
Clinical Studies - Jul 7, 2017 - Jul 7, 2021
Completed
Project leader: Rickli Hans
Members: Gemperle Michaela
Stressbewältigung und Teamstärkung durch Achtsamkeit: Mindfulness Based Intervention
Jul 3, 2017Background Reforms within the health care system subject the entire working conditions, in particular physician- or nurse-patient relation, to the principles of cost-effectiveness with consecutively increasing time pressure. As consequence, stress re...
Clinical Studies - Jul 3, 2017 - Dec 31, 2020
Completed
Project leader: Müller-Käser Iris
Members: Schlaeppi Marc, Fringer André
TOASST
Jul 1, 2017Die Studie soll die Hypothese prüfen, dass auch nach längerer Behandlungsdauer mit Prednison®, Spiricort® oder einem verwandten Produkt auf ein langsames Ausschleichen der Dosis verzichtet werden darf, ohne dass dadurch ein schlechterer Verlauf resul...
Clinical Studies - Jul 1, 2017 - Dec 31, 2025
Ongoing
Project leader: Brändle Michael
Members: Drescher Tilman, Baerlocher Lorenz, Hörburger David, Räss Andrea, Grillmayr Victoria
Preclinical investigation of cardiotoxicity as a clinically important side effect of proteasome inhibitor-based therapy
Jul 1, 2017Carfilzomib is the recently approved second generation proteasome inhibitor for multiple myeloma therapy. Carfilzomib has superior clinical activity than the first generation drug, bortezomib, putatively due to less off-target activity and an altered...
Fundamental Research - Jul 1, 2017 - Jun 30, 2018
Automatically Closed
Project leader: Besse Lenka
Members: Mendez Lopez Max
ECARA
Jun 16, 2017Explore Clinical Utility of Evolocumab in Combination with an e-Health System: Swiss Prospective Observational Study in Patients with clinical Atherosclerotic Cardiovascular Disease (ASCVD) (ECARA)
Clinical Studies - Jun 16, 2017 - Dec 1, 2019
Completed
Project leader: Rickli Hans
Members: Gemperle Michaela
ETOP 10-16 BOOSTER: A randomised phase II trial of osimertinib and bevacizumab versus osimertinib alone as second-line treatment in stage IIIb-IVb NSCLC with con-firmed EGFRm and T790M
Jun 15, 2017First-generation EGFR tyrosine kinase inhibitors provide significant clinical benefit in patients with advanced EGFR-mutant (EGFRm) non–small cell lung carcinoma (NSCLC). However, all patients ultimately develop disease progres-sion, driven – as the...
Clinical Studies - Jun 15, 2017 - Oct 26, 2023
Automatically Closed
Project leader: Früh Martin
HD21 for advanced stages: Treatment optimization trial in the first-line treatment of advanced stage Hodgkin lymphoma; comparison of 6 cy-cles of escalated BEACOPP with 6 cycles of BrECADD
Jun 9, 2017With the establishment of polychemotherapy and the con-tinuous advancements in radiotherapy, Hodgkin lymphoma has meanwhile become a malignant oncological disease in adults with one of the best prognoses of all. The outcome improvements in Hodgkin ly...
Clinical Studies - Jun 9, 2017 - Sep 30, 2021
Automatically Closed
Project leader: Hitz Felicitas
Amiselimod
Jun 1, 2017A Phase 3, Randomized, Double-Blinded, Placebo-Controlled, Multicenter Study of Amiselimod (MT-1303) in the Induction and Maintenance of Clinical Response and Remission in Subjects With Moderate to Severe Ulcerative Colitis
Clinical Studies - Jun 1, 2017 - Sep 27, 2022
Automatically Closed
Members: Knellwolf Christina, Dora Barbara, Krieger-Grübel Claudia, Sulz Michael
Swiss Pituitary Registry
Jun 1, 2017Prospektive Erfassung aller endoskopisch operierten Hypophysentumore SwissPit
Clinical Studies - Jun 1, 2017 - Jun 1, 2021
Automatically Closed
Project leader: Bilz Stefan
Members: Ebert Andrea, Räss Andrea
Coaching im Rahmen der Karriereplanung junger Ärztinnen und Ärzte
Jun 1, 2017Der vielbeschriebene Ärztemangel erfordert neue Konzepte, um die Transition von der Studienzeit in den Berufsalltag und die fachärztliche Weiterbildung gelingen zu lassen. Auch Coaching-Angebote für junge Ärztinnen und Ärzte können in diesem Zusammen...
Healthcare Research - Jun 1, 2017 - Dec 31, 2021
Completed
Project leader: Thanner Mirjam
Members: Winder Franziska, Quenzer Anne, Schlegel A, Von Szadkowski C, Hornung René
PARADISE-MI: Prospective ARNI versus ACE inhibitor trial to DetermIne
May 31, 2017A multi-center, randomized, double-blind, active-controlled, parallelgroup Phase 3 study to evaluate the efficacy and safety of LCZ696 compared to ramipril on morbidity and mortality in high risk patients following an acute myocardial infarction The...
Clinical Studies - May 31, 2017 - Mar 1, 2021
Completed
Project leader: Maeder Micha
Members: Gemperle Michaela
Finch 302 Gilead
May 24, 2017A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Filgotinib Administered for 24 weeks in Combination with Conventional Synthetic Disease-modifying Anti-rheumatic Drug(s) (csDMARDs) to Sub...
Clinical Studies - May 24, 2017 - Sep 26, 2018
Completed
Project leader: Müller Rüdiger
Members: Forrer Silvia, Hutz Carina Liane, Bartz-Batliner Mira, Schmidig Kathrin
CCX_Chemocentryx CL010 CCX168 (Avacopan)
May 15, 2017A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of CCX168 (Avacopan) in Patients with Anti-Neutrophil Cytoplasmic Antibody (ANCA)- Associated Vasculitis Treated Concomitantly with Rituximab or Cycloph...
Clinical Studies - May 15, 2017 - May 31, 2021
Completed
Project leader: Neumann Thomas
Members: Forrer Silvia, Hutz Carina Liane, Bartz-Batliner Mira, Rubbert-Roth Andrea
Exploring the Origins, Characteristics and Implications of Placental Calcification - A Materials Science Approach
May 1, 2017Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (SNF), Abteilung Mathematik, Natur- und Ingenieurwissenschaften
Fundamental Research - May 1, 2017 - Apr 30, 2020
Automatically Closed
Project leader: Herrmann Inge
Members: Hornung René, Rduch Thomas, Neels Antonia, Bertazzo Sergio, Buerki-Thurnherr Tina